Thomas E. Claiborne

Thomas E. Claiborne

Auto-generated profile, based on publicly available information

Thomas E. Claiborne

Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York 11794, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Journal of Biomechanical Engineering
Verified
Journal Article
Closed access
PDF file
TCThomas E. Claiborne
Thomas E. Claiborne
Jawaad SheriffJawaad Sheriff
Jawaad Sheriff
MKMaximilian Kuetting
Maximilian Kuetting
USUlrich Steinseifer
Ulrich Steinseifer
MSMarvin J. Slepian
Marvin J. Slepian
Danny BluesteinDanny Bluestein
Danny Bluestein
Calcific aortic valve disease is the most common and life threatening form of valvular heart disease, characterized by stenosis and regurgitation, which is currently treated at the symptomatic end-stages via open-heart surgical replacement of the diseased valve with, typically, either a xenograft tissue valve or a pyrolytic carbon mechanical heart valve. These options offer the clinician a choice between structural valve deterioration and chronic anticoagulant therapy, respectively, effectively replacing one disease with another. Polymeric prosthetic heart valves (PHV) offer the promise of reducing or eliminating these complications, and they may be better suited for the new transcatheter aortic valve replacement (TAVR) procedure, which currently utilizes tissue valves. New evidence indicates that the latter may incur damage during implantation. Polymer PHVs may also be incorporated into pulsatile circulatory support devices such as total artificial heart and ventricular assist devices that currently employ mechanical PHVs. Development of polymer PHVs, however, has been slow due to the lack of sufficiently durable and biocompatible polymers. We have designed a new trileaflet polymer PHV for surgical implantation employing a novel polymer—xSIBS—that offers superior bio-stability and durability. The design of this polymer PHV was optimized for reduced stresses, improved hemodynamic performance, and reduced thrombogenicity using our device thrombogenicity emulation (DTE) methodology, the results of which have been published separately. Here we present our new design, prototype fabrication methods, hydrodynamics performance testing, and platelet activation measurements performed in the optimized valve prototype and compare it to the performance of a gold standard tissue valve. The hydrodynamic performance of the two valves was comparable in all measures, with a certain advantage to our valve during regurgitation. There was no significant difference between the platelet activation rates of our polymer valve and the tissue valve, indicating that similar to the latter, its recipients may not require anticoagulation. This work proves the feasibility of our optimized polymer PHV design and brings polymeric valves closer to clinical viability.

1 November 2012 in Expert Review of Medical Devices
Verified
Journal Article
Closed access
TCThomas E Claiborne
Thomas E Claiborne
MSMarvin J Slepian
Marvin J Slepian
SHSyed Hossainy
Syed Hossainy
Danny BluesteinDanny Bluestein
Danny Bluestein
Present prosthetic heart valves, while hemodynamically effective, remain limited by progressive structural deterioration of tissue valves or the burden of chronic anticoagulation for mechanical val...

1 May 2013 in ASAIO Journal
Verified
Journal Article
Closed access
TCThomas E. Claiborne
Thomas E. Claiborne
Michalis XenosMichalis Xenos
Michalis Xenos
Jawaad SheriffJawaad Sheriff
Jawaad Sheriff
WCWei-Che Chiu
Wei-Che Chiu
JSJoao Soares
Joao Soares
Danny BluesteinDanny Bluestein
Danny Bluestein
Aortic stenosis is the most prevalent and life-threatening form of valvular heart disease. It is primarily treated via open-heart surgical valve replacement with either a tissue or a mechanical prosthetic heart valve (PHV), each prone to degradation and thrombosis, respectively. Polymeric PHVs may be optimized to eliminate these complications, and they may be more suitable for the new transcatheter aortic valve replacement procedure and in devices like the total artificial heart. However, the development of polymer PHVs has been hampered by persistent in vivo calcification, degradation, and thrombosis. To address these issues, we have developed a novel surgically implantable polymer PHV composed of a new thermoset polyolefin called cross-linked poly(styrene-block-isobutylene-block-styrene), or xSIBS, in which key parameters were optimized for superior functionality via our device thrombogenicity emulation methodology. In this parametric study, we compared our homogeneous optimized polcymer PHV to a prior composite polymer PHV and to a benchmark tissue valve. Our results show significantly improved hemodynamics and reduced thrombogenicity in the optimized polymer PHV compared to the other valves. These results indicate that our new design may not require anticoagulants and may be more durable than its predecessor, and validate the improvement, toward optimization, of this novel polymeric PHV design.

1 January 2011 in ASAIO Journal
Verified
Journal Article
Closed access
TCThomas E. Claiborne
Thomas E. Claiborne
GGGaurav Girdhar
Gaurav Girdhar
SGSiobhain Gallocher-Lowe
Siobhain Gallocher-Lowe
Jawaad SheriffJawaad Sheriff
Jawaad Sheriff
YKYasushi P. Kato
Yasushi P. Kato
DBDanny Bluestein
Danny Bluestein
Trileaflet polymeric prosthetic aortic valves (AVs) produce hemodynamic characteristics akin to the natural AV and may be most suitable for applications such as transcatheter implantation and mechanical circulatory support (MCS) devices. Their success has not yet been realized due to problems of calcification, durability, and thrombosis. We address the latter by comparing the platelet activation rates (PARs) of an improved polymer valve design (Innovia LLC) made from poly(styrene-block-isobutylene-block-styrene) (SIBS) with the commercially available Carpentier-Edwards Perimount Magna Aortic Bioprosthetic Valve. We used our modified prothrombinase platelet activity state (PAS) assay and flow cytometry methods to measure platelet activation of a pair of 19 mm valves mounted inside a pulsatile Berlin left ventricular assist device (LVAD). The PAR of the polymer valve measured with the PAS assay was fivefold lower than that of the tissue valve (p = 0.005) and fourfold lower with flow cytometry measurements (p = 0.007). In vitro hydrodynamic tests showed clinically similar performance of the Innovia and Magna valves. These results demonstrate a significant improvement in thrombogenic performance of the polymer valve compared with our previous study of the former valve design and encourage further development of SIBS for use in heart valve prostheses.

16 June 2010
Verified
Conference Paper
Closed access
PDF file
TCThomas E. Claiborne
Thomas E. Claiborne
GGGaurav Girdhar
Gaurav Girdhar
Jawaad SheriffJawaad Sheriff
Jawaad Sheriff
JJJolyon Jesty
Jolyon Jesty
Marvin SlepianMarvin Slepian
Marvin Slepian
DBDanny Bluestein
Danny Bluestein
Mechanical circulatory support (MCS) devices developed for end-stage heart failure or as a bridge-to-transplant include total artificial hearts (TAH) and ventricular assist devices (VAD) and utilize prosthetic heart valves (PHV) or rotary impellers to control blood recirculation [1]. These devices are currently not optimized to reduce the incidence of pathological flow patterns that cause elevated stresses leading to platelet activation and thrombosis. Although the latter is partially mitigated by lifelong anticoagulation therapy, it dramatically increases the risk of uncontrolled bleeding. For instance thromboembolic stroke-related complications (∼2%) were relatively less with the TAH-t compared to uncontrolled bleeding due to anticoagulation use (∼20%) [2]. Platelet activation should therefore be quantified and optimized based on patient-specific cardiac outputs in device prototypes before clinical use.